Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study
Background/Aims The World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination. M...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2025-04-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2024-0664.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850196986537443328 |
|---|---|
| author | Meiyu Wu Jing Ma Xuehong Wang Sini Li Chongqing Tan Ouyang Xie Andong Li Aaron G Lim Xiaomin Wan |
| author_facet | Meiyu Wu Jing Ma Xuehong Wang Sini Li Chongqing Tan Ouyang Xie Andong Li Aaron G Lim Xiaomin Wan |
| author_sort | Meiyu Wu |
| collection | DOAJ |
| description | Background/Aims The World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination. Methods Using an HCV transmission compartmental model, we evaluated the benefits and costs of different strategies combining screening and treatment for Chinese populations. We identified strategies to achieve HCV elimination and calculated the incremental cost-effectiveness ratios (ICERs) per disability-adjusted life year (DALY) averted for 2022–2030 to identify the optimal elimination strategy. Furthermore, we estimated the ROI by 2050 by comparing the required investment with the economic productivity gains from reduced HCV incidence and deaths. Results The strategy that results in the most significant health benefits involves conducting annual primary screening at a rate of 14%, re-screening people who inject drugs annually and the general population every five years, and treating 95% of those diagnosed (P14-R4-T95), preventing approximately 5.75 and 0.44 million HCV infections and deaths, respectively, during 2022–2030. At a willingness-to-pay threshold of $12,615, the P14-R4-T95 strategy is the most cost-effective, with an ICER of $5,449/DALY. By 2050, this strategy would have a net benefit of $120,997 million (ROI=0.868). Conclusions Achieving HCV elimination in China by 2030 will require significant investment in large-scale universal screening and treatment, but it will yield substantial health and economic benefits and is cost-effective. |
| format | Article |
| id | doaj-art-47b2f57e2a8b4df8af83f881a79f3fd3 |
| institution | OA Journals |
| issn | 2287-2728 2287-285X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj-art-47b2f57e2a8b4df8af83f881a79f3fd32025-08-20T02:13:19ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2025-04-0131239440810.3350/cmh.2024.06642112Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling studyMeiyu Wu0Jing Ma1Xuehong Wang2Sini Li3Chongqing Tan4Ouyang Xie5Andong Li6Aaron G Lim7Xiaomin Wan8 Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaBackground/Aims The World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination. Methods Using an HCV transmission compartmental model, we evaluated the benefits and costs of different strategies combining screening and treatment for Chinese populations. We identified strategies to achieve HCV elimination and calculated the incremental cost-effectiveness ratios (ICERs) per disability-adjusted life year (DALY) averted for 2022–2030 to identify the optimal elimination strategy. Furthermore, we estimated the ROI by 2050 by comparing the required investment with the economic productivity gains from reduced HCV incidence and deaths. Results The strategy that results in the most significant health benefits involves conducting annual primary screening at a rate of 14%, re-screening people who inject drugs annually and the general population every five years, and treating 95% of those diagnosed (P14-R4-T95), preventing approximately 5.75 and 0.44 million HCV infections and deaths, respectively, during 2022–2030. At a willingness-to-pay threshold of $12,615, the P14-R4-T95 strategy is the most cost-effective, with an ICER of $5,449/DALY. By 2050, this strategy would have a net benefit of $120,997 million (ROI=0.868). Conclusions Achieving HCV elimination in China by 2030 will require significant investment in large-scale universal screening and treatment, but it will yield substantial health and economic benefits and is cost-effective.http://e-cmh.org/upload/pdf/cmh-2024-0664.pdfhepatitis cdisease eradicationcost-effectiveness analysisoutcome assessment, health carechina |
| spellingShingle | Meiyu Wu Jing Ma Xuehong Wang Sini Li Chongqing Tan Ouyang Xie Andong Li Aaron G Lim Xiaomin Wan Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study Clinical and Molecular Hepatology hepatitis c disease eradication cost-effectiveness analysis outcome assessment, health care china |
| title | Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study |
| title_full | Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study |
| title_fullStr | Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study |
| title_full_unstemmed | Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study |
| title_short | Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study |
| title_sort | cost effectiveness and return on investment of hepatitis c virus elimination in china a modelling study |
| topic | hepatitis c disease eradication cost-effectiveness analysis outcome assessment, health care china |
| url | http://e-cmh.org/upload/pdf/cmh-2024-0664.pdf |
| work_keys_str_mv | AT meiyuwu costeffectivenessandreturnoninvestmentofhepatitiscviruseliminationinchinaamodellingstudy AT jingma costeffectivenessandreturnoninvestmentofhepatitiscviruseliminationinchinaamodellingstudy AT xuehongwang costeffectivenessandreturnoninvestmentofhepatitiscviruseliminationinchinaamodellingstudy AT sinili costeffectivenessandreturnoninvestmentofhepatitiscviruseliminationinchinaamodellingstudy AT chongqingtan costeffectivenessandreturnoninvestmentofhepatitiscviruseliminationinchinaamodellingstudy AT ouyangxie costeffectivenessandreturnoninvestmentofhepatitiscviruseliminationinchinaamodellingstudy AT andongli costeffectivenessandreturnoninvestmentofhepatitiscviruseliminationinchinaamodellingstudy AT aaronglim costeffectivenessandreturnoninvestmentofhepatitiscviruseliminationinchinaamodellingstudy AT xiaominwan costeffectivenessandreturnoninvestmentofhepatitiscviruseliminationinchinaamodellingstudy |